LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic capital allocation initiative to acquire cryptocurrency as part of its corporate treasury. The Board approved allocation of up to 25 percent of its treasury to cryptocurrencies, including Bitcoin and potentially other digital assets as it deems appropriate.